Skip to main content (Press Enter).
Toggle navigation
Department of Defense Manufacturing Technology Program
Department of Defense Manufacturing Technology Program
Search
Search Department of Defense Manufacturing Technology Program:
Search
Search Department of Defense Manufacturing Technology Program:
Search
Home
OSD ManTech
DoD ManTech
History
OSD's MSTP
Army ManTech
Navy ManTech
Air Force ManTech
DLA ManTech
MDA ManTech
JDMTP
AME Subpanel
Composites Subpanel
Electronics Subpanel
Metals Subpanel
Manufacturing Innovation Institutes
America Makes
MxD
LIFT
AIM Photonics
NextFlex
AFFOA
BioFabUSA
ARM Institute
BioMADE
Manufacturing Collaborations
Subcommittee on Advanced Manufacturing
Manufacturing USA
Joint Defense Manufacturing Council
Joint Additive Manufacturing Working Group
Manufacturing Extension Partnership
Education and Workforce Development
ManTech EWD Initiatives
Biographies
News
Success Stories
Engage
BioFabUSA — Advanced Regenerative Manufacturing Institute
BioFabUSA Fast Facts
Established
December 2016
Website
armiusa.org
Mission
Make practical the scalable, consistent, and cost-effective manufacturing of cells, tissues, and organs and develop the trained and ready workforce necessary for that manufacturing.
Headquarters
Manchester, NH
Consortium Organizer
Advanced Regenerative Manufacturing Institute (ARMI)
Institute Metrics as of December 31, 2021
163
Member Organizations
Total Committed Funding on Original and Follow-on Agreements with DoD
$80M
Base Federal Funding
$214M
Base Non-Federal Cost Share
Additional Committed Project Funding
$33M
DoD Projects
$6M
Academia/Industry Projects
Total Ongoing and Completed Projects
46
Technology Projects
15
Education and Workforce Development (EWD) Projects
Education and Workforce Development
16,129
Participants in EWD Projects or Institute-led EWD Activities in Fiscal Year (FY) 2021
Successes
Click here for the latest DoD MII Success Stories.
Institute Snapshot
Significant breakthroughs in cell biology, biofabrication, and materials science in the last decade have laid the foundation for scalable manufacturing and commercialization of engineered tissues and tissue-related technologies. BioFabUSA has targeted the raw material, equipment, measurement, automation, logistics and big data analytics challenges that hinder scalable, consistent, and cost-effective manufacturing. The development of tissue-engineered medical products on an industrial scale enables DoD to accelerate creation of numerous medical products for our wounded warfighters, which support force readiness and save lives on the battlefield.
BioFabUSA's Tissue Foundry
Institute Capabilities
BioFab Foundry
BioFabUSA developed the first-ever BioFab Foundry manufacturing platform. The Tissue Foundry (shown above) is composed of a series of subsystems, or modules, each representing a different stage of the manufacturing process for cells, tissues and organs — from culture of the cells that make up the tissue to packaging of the final product. Modularity allows users to scale up and reconfigure the platform to facilitate the manufacture of all cells, tissues, and organs. Integration of programmable automation allows monitoring and data logging of process parameters in the short term, and opens the door to process control through big data analytics, machine learning and artificial intelligence in the long term. Automation allows for cost-effective operations at scale. Finally, because the system is closed, the risk of contamination and process variability introduced by exposure to ambient air is mitigated significantly. This eliminates the need for costly capital investments in clean room facilities. Modular, automated and closed manufacturing will ensure that the warfighter and the nation have access to sufficient numbers of effective, consistent, and affordable cells, tissues and organs.
Deep Tissue
Characterization Center
The Deep Tissue Characterization Center is an integrated system of analytical instrumentation that supports the in-depth analysis of cells, culture media, and engineered tissues, including characterization of cell count/viability, apoptosis, multi-omics (e.g., transcriptome, proteome, lipidome, metabolome), and other product-specific functional assays. This analysis of cells, culture media, and tissues correlates with successful production runs and clinical trial results to determine critical process parameters for the automated control of tissue manufacturing.
Education & Workforce
Development
BioFabUSA is working to close educational skills gaps in tissue engineering and organ manufacturing through accessible educational and training opportunities. Over 5,000 students have already participated in the developed activities. The kit is “productized” with complete instructions, including a teacher guide and student guide, with questions aligned to the Next Generation Science Standards, Common Core Standards, and the Framework for K-12 Science Education. These kits provide opportunities to highlight essential manufacturing skills and processes and allow students to envision a career pathway for themselves in this emerging technology area, ultimately attracting the future workforce to the biofabrication industry. As the industry continues to evolve, BioFabUSA is responding to the growing industry-driven demand and is working to educate the current workforce needed for scalable manufacture of cells, tissues and organs through various Certificate & Training Programs.